Oncology and Liquid Biopsy
POLE-POLD1 mutations are changes in genes responsible for DNA replication and proofreading, leading to increased DNA mutations and a condition called Polymerase Proofreading-Associated Polyposis (PPAP) syndrome. These mutations increase the risk of various cancers, such as colorectal, endometrial, and brain cancers, but are often associated with a good prognosis and a high tumor mutational burden, which can make tumors more susceptible to immunotherapy.
Multiplexed ctDNA fragments (~150bp) mixed with nucleosomally fragmented wildtype cfDNA background in human plasma. The cell-derived ctDNA fragments are generated by Anchor’s unique multiplexed gene-editing method and are nucleosomally fragmented to around 150bp. The cell-derived variants are suitable for both the amplicon-based and capture-based methods. The synthetic ctDNA fragments are gBlocks-like dsDNA of 150-170bp and are suitable for amplicon-based applications, including ddPCR, qPCR, and amplicon-based NGS.
AM Normal cfgDNA-1
Description: DNA is extracted and fragmented from a popular normal male cell line
| Product Name | Cat. No. | Size (vial) |
|---|---|---|
| AM Normal cfgDNA-1 (Dissolved in TE) | 60133001 | 1ug per vial |
| AM Normal cfgDNA-1 (Spiked in Plasma) | 60133501 | Pre-spiked with 125ng gDNA per 5ml |
Twenty-three Multiplexed nucleosomally fragmented ctDNA fragments (~150bp) mixed with normal patient cfDNA background in human plasma. The cell-derived ctDNA fragments are generated by Anchor’s unique multiplexed gene-editing method and are nucleosomally fragmented to around 150bp. The cell-derived variants are suitable for capture-based methods.
For customer SNV/indel/fusion variants for either cfDNA assays or solid tumor tests, please request by clicking the “Order Here” button and select the “Customer Molecular Controls” option.
Does your cfDNA extraction process affect the Limit of Detection (LOD) of a particular gene target? Our new products, cfDNA Extraction Sensitivity Panels and Extraction Low Positive Controls, can help your research and development for liquid biopsy assays.
For customized fusion solutions, please contact us at: info@anchormolecular.com
+1 925-400-9986 for ordering
The BCR-ABL Control Panels are intended for use as reference material to monitor the performance of the in vitro quantitative detection of BCR-ABL1 translocation mRNA e14a2 (p210), e13a2 (p210), e1a2 (p190) transcripts and the ABL1 endogenous control mRNA transcript. The products consist of purified RNA transcripts meticulously blended to give from 10%IS (MR1.0) down to 0.001%IS (MR5.0). They work well on the Xpert® BCR-ABL Ultra assay on Cepheid GeneXpert® Instrument Systems.
The Plasma Genomic cfDNA Extraction Control is for the purpose of monitoring the degree of genomic DNA (gDNA) contamination in the extracted cfDNA. DNA-free plasma is spiked with either with high molecular weight gDNA molecules or 170 bp cfDNA fragments or both.